Clinical Trial VICCTHN1242


A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Principal Investigator(s)

Leora Horn


  • Protocol No. VICCTHN1242
  • Open Date: 10/24/2012
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: The primary objectives of the study are to: - Determine the safety and tolerability of CC-223 when administered orally in combination with either erlotinib or oral azacitidine and to define the non-tolerated dose (NTD) and the maximum tolerated dose (MTD) of each combination. - Characterize the pharmacokinetics (PK) of CC-223 and azacitidine following oral administration as single agents and after combination treatment.
  • Disease Sites: Lung; Non Small Cell
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Azacitidine; CC-223; Tarceva (OSI-774; erlotinib)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01545947
  • Secondary Protocol No: CC-223-NSCL-001



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.